Safety of IGIV therapy and infusion-related adverse events.
about
Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosisNew approaches to treatment of primary immunodeficiencies: fixing mutations with chemicalsClinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization6th International Immunoglobulin Symposium: poster presentations.Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.Immune mediated diseases and immune modulation in the neurocritical care unitAttenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein EfbSubcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Immunoglobulin replacement therapy in children.Primary immunodeficiencies of the B lymphocyteTreatment of multifocal motor neuropathy with intravenous immunoglobulin.Hizentra for the treatment of primary immunodeficiency.Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases.Biologics in dermatology: adverse effects.Kawasaki Disease Masquerading as Hepatitis: A Diagnostic Challenge for Pediatricians.A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.Dosing and therapy utilization: a discussion of updates on PI treatment guidelines.Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease
P2860
Q24201599-9BB49A57-E4D9-4DC1-AFA9-C9A1E0C035A0Q24656619-6C5A564C-96D6-477E-92D2-4D5E5E732E96Q26741124-D8AD2A8E-5E63-4508-B139-16AE77870272Q33386923-E21F6749-F3AC-4624-A12A-202158C2DE93Q33401630-77C1552E-E079-43A0-9B0C-937607C2E54CQ33692418-CDD38016-CF62-48F4-8444-D4239BDA7074Q33901517-CD4108F8-3886-45F2-878C-0BED031593E1Q35729575-35EB954C-618A-4B69-ADCF-823FFD61AB1DQ35765208-54F93CEB-1596-44B1-8254-0CC8C13B36C9Q36196688-94343ED1-0B71-4D09-803D-D70E539BAAE0Q36979273-F5071F44-8CCC-4E7C-B83B-D685C494ECFCQ37714868-6A9D0AB2-E99A-423D-98C6-28228F80E81DQ38202020-568BD09A-F741-42ED-8130-CF6685431372Q38245612-001989B0-6115-4EB4-A9FC-215D80693A8DQ40234039-7AFCBF8A-9529-4086-B2DC-28EFBBF01341Q41120913-29F02ED2-1DF8-4166-8F51-962987858953Q42172881-73EED60D-E879-4C56-A669-BFF6E9AAE644Q42654125-2FCBDF11-B5C3-4CE9-A4DA-E563F294A56DQ46048428-28A07B08-AB4A-4C67-8DA7-18DFC9A11997Q46267598-12CC740B-3CBE-4443-B44C-195CB9B8F6FCQ47217747-AE2A647B-E118-4332-963D-35D6B1BB161CQ57024630-288A227F-2D1B-48B6-A96B-0C28D6920970
P2860
Safety of IGIV therapy and infusion-related adverse events.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Safety of IGIV therapy and infusion-related adverse events.
@en
type
label
Safety of IGIV therapy and infusion-related adverse events.
@en
prefLabel
Safety of IGIV therapy and infusion-related adverse events.
@en
P1433
P1476
Safety of IGIV therapy and infusion-related adverse events.
@en
P2093
Mark Ballow
P2888
P304
P356
10.1007/S12026-007-0003-5
P577
2007-01-01T00:00:00Z